Iqvia Holdings Inc (NYSE:IQV) Expected to Announce Quarterly Sales of $2.76 Billion

Analysts expect Iqvia Holdings Inc (NYSE:IQV) to announce sales of $2.76 billion for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Iqvia’s earnings, with the lowest sales estimate coming in at $2.75 billion and the highest estimate coming in at $2.77 billion. Iqvia reported sales of $2.59 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.6%. The business is expected to report its next earnings report on Monday, October 28th.

On average, analysts expect that Iqvia will report full year sales of $11.08 billion for the current financial year, with estimates ranging from $11.04 billion to $11.12 billion. For the next year, analysts expect that the company will report sales of $11.87 billion, with estimates ranging from $11.84 billion to $11.92 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Iqvia.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, beating the consensus estimate of $1.38 by $0.01. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. During the same period in the previous year, the business earned $1.29 earnings per share. The company’s revenue was up 6.7% on a year-over-year basis.



Several research analysts have commented on IQV shares. Wells Fargo & Co boosted their price objective on shares of Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Morgan Stanley boosted their target price on shares of Iqvia from $156.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 19th. Credit Suisse Group boosted their target price on shares of Iqvia from $165.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Barclays set a $180.00 target price on shares of Iqvia and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, Mizuho raised shares of Iqvia from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $150.00 to $175.00 in a research note on Friday, June 21st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $163.09.

In related news, insider Kevin C. Knightly sold 4,278 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $158.50, for a total value of $678,063.00. Following the sale, the insider now owns 4,084 shares of the company’s stock, valued at $647,314. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,616,028 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $156.85, for a total transaction of $410,323,991.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,627,251 shares of company stock worth $412,103,046. Insiders own 6.00% of the company’s stock.

Several institutional investors have recently modified their holdings of IQV. CWM LLC grew its stake in shares of Iqvia by 63.4% in the second quarter. CWM LLC now owns 165 shares of the medical research company’s stock worth $27,000 after purchasing an additional 64 shares during the last quarter. Capital Investment Advisory Services LLC grew its stake in shares of Iqvia by 46.0% in the second quarter. Capital Investment Advisory Services LLC now owns 219 shares of the medical research company’s stock worth $34,000 after purchasing an additional 69 shares during the last quarter. Massmutual Trust Co. FSB ADV bought a new stake in shares of Iqvia in the second quarter worth $35,000. North Star Investment Management Corp. bought a new stake in shares of Iqvia in the third quarter worth $59,000. Finally, Cornerstone Advisors Inc. grew its stake in shares of Iqvia by 47.2% in the second quarter. Cornerstone Advisors Inc. now owns 399 shares of the medical research company’s stock worth $64,000 after purchasing an additional 128 shares during the last quarter. 89.67% of the stock is currently owned by institutional investors.

IQV traded up $1.08 during trading on Friday, hitting $145.97. 35,611 shares of the stock traded hands, compared to its average volume of 1,678,106. Iqvia has a twelve month low of $104.90 and a twelve month high of $164.13. The company has a market cap of $28.31 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 1.60 and a beta of 0.89. The company has a debt-to-equity ratio of 1.72, a current ratio of 1.14 and a quick ratio of 1.14. The business has a 50 day moving average price of $151.91 and a 200 day moving average price of $147.78.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What causes a recession?

Get a free copy of the Zacks research report on Iqvia (IQV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.